Chikungunyavirussykdom
Sist revidert:
Sist revidert av:Ingard Løge
Definisjon:
Myggoverført virussykdom med feber og leddsmerter. Sykdommen er nesten alltid selvbegrensende
Forekomst:
Sykdommen forekommer normalt i deler av Afrika, det indiske subkontinent, i Sørøst-Asia og Karibien
Symptomer:
Feber og leddsmerter. Hos noen kan leddsmertene vedvare i måneder
Funn:
Feber og moderat redusert allmenntilstand
Diagnostikk:
Tilleggsundersøkelser er antistoffpåvisning i serum eller PCR
Behandling:
Symptomatisk behandling
- Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. PubMed
- Smittevernveilederen. Chikungunyavirus-sykdom - veileder for helsepersonell. Folkehelseinstituttet, sist oppdatert 13.01.2018.
- Morens DM, Fauci AS. Chikungunya at the door--déjà vu all over again? N Engl J Med 2014; 371:885. New England Journal of Medicine
- Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231. New England Journal of Medicine
- Gerardin P, Couderc T, Bintner M, et al. Chikungunya virus - associated encephalitis. Neurology 2015. doi:10.1212/WNL.0000000000002234
- Parola P, de Lamballerie X, Jourdan J, et al. Novel Chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006; 12: 1493-9. PubMed
- Centers for Disease Control and Prevention. Chikungunya Virus. Symptoms, Diagnosis and Treatment. 2022. www.cdc.gov
- Charrel RN, de Lamballerie X,Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007; 356: 769-71. PubMed
- Simon F, Savini H, Parola P. Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am 2008; 92:1323. PubMed
- Ferreira AC, Reis PA, de Freitas CS, et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother. 2018. pmid:30455237 PubMed
- EPR (European pharmaceutical review). News 6.8.2021. Chikungunya vaccine effective in 98.5 percent of participants www.europeanpharmaceuticalreview.com
- Valneva. Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate. Published March 8, 2022. valneva.com
- Ingard Løge, spesialist i allmennmedisin, redaktør NEL